Walleye Capital
SABSW icon

Walleye Capital’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Walleye Capital’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23,258
Closed -$837 – 5459
2024
Q3 		$837 Hold
23,258
– – ﹤0.01% 5147
2024
Q2 		$1.1K Hold
23,258
– – ﹤0.01% 5471
2024
Q1 		$907 Hold
23,258
– – ﹤0.01% 5325
2023
Q4 		$702 Hold
23,258
– – ﹤0.01% 4829
2023
Q3 		$1.63K Hold
23,258
– – ﹤0.01% 4728
2023
Q2 		$2.43K Hold
23,258
– – ﹤0.01% 4133
2023
Q1 		$837 Hold
23,258
– – ﹤0.01% 3836
2022
Q4 		$1.09K Hold
23,258
– – ﹤0.01% 3048
2022
Q3 		$1K Hold
23,258
– – ﹤0.01% 3129
2022
Q2 		$3K Hold
23,258
– – ﹤0.01% 2202
2022
Q1 		$11K Hold
23,258
– – ﹤0.01% 2079
2021
Q4 		$42K Sell
23,258
-25,135
-52% -$46.1K ﹤0.01% 1797
2021
Q3 		$45 Buy
48,393
+3,393
+8% +$2.42K ﹤0.01% 1401
2021
Q2 		$41 Buy
+45,000
New +$32.7K ﹤0.01% 1244

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Walleye Capital's SABSW Position: Q4 2024 in Review

Walleye Capital sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2024, closing a stake of 23,258 shares — an estimated $837 sold.

Walleye Capital first reported a position in SABSW in Q2 2021 and held it in 14 quarters. The position peaked at $42K in Q4 2021. 9 funds tracked by Wall St. Rank hold SABSW as of Q4 2024.

  • Walleye Capital reported no remaining SAB Biotherapeutics Warrant position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 23,258 SAB Biotherapeutics Warrant shares in Q4 2024, an estimated $837.
  • Walleye Capital first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 14 quarters.
  • Walleye Capital's SAB Biotherapeutics Warrant position peaked at $42K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.